<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02830477</url>
  </required_header>
  <id_info>
    <org_study_id>18559</org_study_id>
    <secondary_id>KV1601</secondary_id>
    <nct_id>NCT02830477</nct_id>
  </id_info>
  <brief_title>Study Evaluating &quot;Real World&quot; Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis</brief_title>
  <acronym>TAURUS</acronym>
  <official_title>A Multinational Phase IV Study Evaluating &quot;Real World&quot; Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate weekly prophylaxis dosing regimens used
      in standard clinical practice.

      In addition the study will capture reported bleed rate, pattern of change in KOVALTRY
      prophylaxis dose &amp; dosing frequency, reason for choice of treatment regimen, FVIII product
      switch pattern, patient treatment satisfaction and adherence, KOVALTRY pharmacokinetic data
      (if performed), KOVALTRY consumption, as well as safety data.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, prospective, non-interventional, single arm study in patients receiving KOVALTRY
      as prophylaxis therapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 14, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients on 2x weekly prophylaxis</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients on 3x weekly prophylaxis</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite number of reported bleeds (total, spontaneous, joint and trauma)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in predefined prophylaxis regimen per age group and per country</measure>
    <time_frame>At the end of observational period, up to 12 months maximum</time_frame>
    <description>Age group:
0- &lt;6 years
6 - 12 years
13 - &lt;18 years
&gt; 18 years
Weekly prophylaxis dosing regimens:
2 injections a week
3 injections a week
Injected on every other day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall prophylaxis dose IU/kg in patients per age group and per country</measure>
    <time_frame>At the end of observational period, up to 12 months maximum</time_frame>
    <description>Age group:
0- &lt;6 years
6 - 12 years
13 - &lt;18 years
&gt; 18 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of physicians who selected the individual criteria as top 3 reason for the prophylaxis decision</measure>
    <time_frame>At baseline</time_frame>
    <description>Physician will select top 3 reasons from Age, i.v. access, Current treatment regimen, Bleeding history with current treatment regimen, Prior history of life threatening bleed, Number of target joints, Pharmacokinetic data, Adherence/Compliance history, Activity level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and median composite score for treatment satisfaction (Hemo-SAT)</measure>
    <time_frame>At baseline and end of observational period, up to 12 months maximum</time_frame>
    <description>Hemo-SAT - Hemophilia treatment satisfaction questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score for treatment adherence (VERITAS-PRO)</measure>
    <time_frame>At baseline, 6 months and end of observational period, up to 12 months maximum</time_frame>
    <description>VERITAS - Validated Hemophilia Regimen Treatment Adherence Scale-Prophylaxis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of events of special interest, such as inhibitors</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of physicians used one or more predefined KOVALTRY PK parameter(s) to define the dose in clinical practice</measure>
    <time_frame>At routine visits, up to 12 months maximum</time_frame>
    <description>Pharmacokinectic parameters
Area under the curve (AUC)
Clearance (Cl)
Half-life
FVIII trough
FVIII peak levels
In-vivo recovery</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">314</enrollment>
  <condition>Hemophilia A, Congenital</condition>
  <arm_group>
    <arm_group_label>BAY81-8973</arm_group_label>
    <description>Previously treated patients receiving IV infusion of KOVALTRY for routine prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973</intervention_name>
    <description>unmodified, full length recombinant FVIII</description>
    <arm_group_label>BAY81-8973</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Previously treated male patients with moderate to severe (≤ 5% FVIII:C) hemophilia A, with
        ≥ 50 exposure days (EDs) to any FVIII product and with or without history of inhibitors who
        have been prescribed KOVALTRY for a medically appropriate use will be eligible to be
        included into this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients diagnosed with moderate to severe hemophilia A (≤ 5% FVIII:C (Factor
             VIII Coagulant activity))

          -  Any age

          -  ≥ 50 exposure days (EDs) to any FVIII product

          -  Patients with or without history of inhibitors

               -  Patient with previous history of inhibitors, with at least 2 consecutive negative
                  inhibitor tests and on standard prophylaxis therapy for at least 1 year prior to
                  study entry

               -  No current evidence of FVIII inhibitor or clinical suspicion of FVIII inhibitor

                    -  Evidence of FVIII inhibitor as measured by the Nijmegen-modified Bethesda
                       assay[&lt;0.6 Bethesda units (BU/mL)] or Bethesda assay [&lt; 1.0 BU/mL] in 2 on
                       consecutives samples

                    -  Documented or clinical suspicion of shortened FVIII half-life (&lt; 6 hrs)

          -  Currently on or plan to start prophylaxis therapy with KOVALTRY

          -  Written informed consent

        Exclusion Criteria:

          -  Patients participating in an investigational program with interventions outside of
             routine clinical practice

          -  Patients with an additional diagnosis of any bleeding/coagulation disorder other than
             hemophilia A

          -  Patients on Immune Tolerance Induction (ITI) treatment at the time of enrollment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Rehabilitation Services/ University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hemophilia and Thrombosis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Division of Pediatric Hematology/Oncology - Jacksonsville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital Adult Hemophilia and Thrombosis Treatment Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Center for Bleeding and Blood Clotting Disorders</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemophilia Center of Western New York</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University - Brody School of Medicine</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at OU Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Hemophilia &amp; Thrombosis Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Center for Bleeding Disorders / Blood Center of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Luxembourg</country>
    <country>Netherlands</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Slovakia</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2016</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Previously treated patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

